Drug-coated balloonsAcute coronary syndromePercutaneous Coronary InterventionDrug-eluting stentsAcute coronary syndromes (ACS) are a major global health concern. Percutaneous coronary intervention (PCI) with new-generation drug-eluting stents (DES) has been endorsed as safe and effective in the management...
Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. Clin Res Cardiol 2013;102:785-97.Kleber FX;Rittger H;Bonaventura K;.Drug-coated balloons for treatment of coronary artery disease:updated recommendations from a consensus group.Clin Res ...
DCB drug-coated balloon DES drug-eluting stent(s) FFR fractional flow reserve ISR in-stent restenosis MB main branch PCI percutaneous coronary intervention SB side branch Drug-coated balloons (DCBs) are a novel treatment strategy for coronary artery disease based on the fast and homogenous transfer...
14.将来新型药物球囊的研发,可能不止有紫杉醇,但首先要循证医学证明其有效性,其次考究其安全性和效率。目前的证据未提示紫杉醇可以明显增加死亡率。 Source:Drug-Coated Balloons for Coronary Artery Disease Third Report of the International DCB Consensus Group...
Early exposure to the use of drug-coated balloons (DCBs) for percutaneous coronary intervention (PCI) “opened my eyes to a whole new world of angioplasty without putting stents in,” Simon Eccleshall (Norwich, UK) tells Cardiovascular News, detailing how the technology has come to play an imp...
Drug-coated balloons (DCB) are gaining attraction worldwide for the treatment of peripheral and coronary lesions. The basic prerequisite for this therapy is the best possible lesion preparation. DCBs cannot replace drug-eluting stents, but will play an important role in the reduction of permanent ...
San Francisco — For the treatment of coronary artery in-stent restenosis,angioplastywith a drug-coated balloon (AGENT DCB; Boston Scientific) was superior to conventional balloon angioplasty in preventing target lesion failure at 1 year in a high-risk patient population. ...
Scheller B, Fontaine T, Mangner N, et al. A novel drug-coated scoring balloon for the treatment of coronary in-stent restenosis: Results from the multi-center randomized controlled PATENT-C first in human trial. Catheter Cardiovasc Interv 2016;88:51-9....
However, late stent thrombosis and restenosis, with a hazard of nearly 2% per year after implantation, remained a concern (1) and motivated the development of drug-coated balloons (DCB). The rationale of DCB technology was a combination therapy of balloon and drug to treat coronary lesions, ...
coronary angiography seen in both beating and non-beating heart; angulation lesions defined as lesion angle> 45°. Ostial lesions defined as within 3 mm of the LM or right coronary artery (RCA) ostium. All DCB of the study were paclitaxel-coated balloons, including Sequent®Please (Braun, ...